Your browser doesn't support javascript.
Clinicopathological association of mucormycosis in COVID 19 pandemic.
Varshney, Mradul; Saxena, Ayushi; Binnani, Nidhi; Kumar, Vanita; Vyas, S P.
  • Varshney M; Department of Pathology, Sardar Patel Medical College, Bikaner, Rajasthan, India.
  • Saxena A; Department of Pathology, Sardar Patel Medical College, Bikaner, Rajasthan, India.
  • Binnani N; Department of Pathology, Sardar Patel Medical College, Bikaner, Rajasthan, India.
  • Kumar V; Department of Pathology, Sardar Patel Medical College, Bikaner, Rajasthan, India.
  • Vyas SP; Department of Pathology, Sardar Patel Medical College, Bikaner, Rajasthan, India.
Indian J Pathol Microbiol ; 66(1): 101-105, 2023.
Article in English | MEDLINE | ID: covidwho-2236587
ABSTRACT
Context Coinfection and superadded infections in patients with coronavirus disease 2019 (COVID-19) has been reported on multiple series. The emerging second wave of the pandemic has come with a lot of changes, especially in developing countries like India. One of such changes is sudden, significant rise in mucormycosis cases.

Aims:

To find out clinicopathological association of invasive mucormycosis with COVID-19 infection status and immunocompromised state. Settings and

Design:

A cross-sectional study done at a tertiary care centre. Methods and

Material:

All cases admitted in the dedicated mucormycosis ward between 1-06-2021 and 15-06-2021 were included in the study. The cases were admitted with suspicion of mucormycosis. The histopathological results were correlated with KOH mount and radiological reports. The clinicopathological association of occurrence of mucormycosis in post-covid and non-COVID patients along with other risk factors. Statistical Analysis Used Odds ratio, chi square test were used to find the association using MS Excel 2010 and SPSS.

Results:

Thirty-six (81.82%) cases were of the post-COVID status, and 8 cases were non-COVID status. Out of 36 post-COVID patients, 33 (91.67%) showed evidence of invasive mucormycosis and of 8 non-COVIDpatients, 7 had evidence of mucormycosis (odds ratio = 1.57). Out of the total diagnosed cases of mucormycosis, 21 (52.5%) patients were known cases of diabetes mellitus (DM), and 7 (17.5%) cases of newly diagnosed hyperglycemia. Thirty (75%) patients out of 40 had some form of immunocompromised state. This shows statistically significant association of DM and immunocompromised state with the occurrence of mucormycosis in post-COVID patients (chi square value2 = 6.891, P value = 0.008). Twenty-five patients had the history of steroid use during the treatment of COVID-19.

Conclusions:

The infection with COVID-19 definitely increases the odds of contracting mucormycosis, but most of the cases had diabetes mellitus. So, it is possible that COVID-19 virus predisposes individuals to invasive fungal infection by precipitating DM.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coinfection / COVID-19 / Mucormycosis Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Indian J Pathol Microbiol Year: 2023 Document Type: Article Affiliation country: Ijpm.ijpm_699_21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Coinfection / COVID-19 / Mucormycosis Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Indian J Pathol Microbiol Year: 2023 Document Type: Article Affiliation country: Ijpm.ijpm_699_21